ACE-inhibitor therapy and survival among patients with multiorgan dysfunction syndrome (MODS) of cardiac and non-cardiac origin

International Journal of Cardiology

Volumn 140, Issue 3, 2010, Pages 296-303

  Schmidt, Hendrik ^a   Hoyer, Dirk ^b   Rauchhaus, Mathias ^c   Prondzinsky, Roland ^a   Hennen, Ralf ^a   Schlitt, Axel ^a   Carter, Justin ^a   Hottenrott, Kuno ^a   Müller Werdan, Ursula ^a   Werdan, Karl ^a   Buerke, Michael ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

ACE inhibitor therapy; APACHE II score; Multiple organ dysfunction syndrome; Sepsis

Indexed keywords

C REACTIVE PROTEIN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL;

ACUTE CORONARY SYNDROME; ADULT; APACHE; ARTICLE; CARDIOGENIC SHOCK; CONTROLLED STUDY; FEMALE; HEART FAILURE; HEART RATE VARIABILITY; HUMAN; INTENSIVE CARE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SURVIVAL RATE; VAGUS TONE; VALVULAR HEART DISEASE; AUTONOMIC NERVOUS SYSTEM; DRUG EFFECT; MIDDLE AGED; RETROSPECTIVE STUDY; SURVIVAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; APACHE; AUTONOMIC NERVOUS SYSTEM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; RETROSPECTIVE STUDIES; SHOCK, CARDIOGENIC; SURVIVAL ANALYSIS;

EID: 77954944607     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.11.104     Document Type: Article

References (42)

1. Moerer O, Schmid A, Hofmann M, et al. Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med 2000;28:1440-6.
2. Schmidt H, Müller-Werdan U, Hoffmann T, et al. Autonomic dysfunction predicts mortality in patients with multiple organ dysfunction syndrome of different age groups. Crit Care Med 2005;33: 1994-2002.
3. Tracey KJ. The inflammatory reflex. Nature 2002;420:853-9.
4. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000;405:458-62.
5. Libert C. Inflammation: a nervous connection. Nature 2003;421:328-9 [Comment on: Nature 2003; 421:384-8].
6. Schmidt H, Hennen R, Keller A, et al. Association of statin therapy and increased survival in patients with multiorgan dysfunction syndrome. Intensive Care Med 2006;32:1248-51.
7. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35.
8. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
9. Ferrario CM, StrawnWB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006;98:121-8.
10. Routledge HC, Chowdhary S, Townend JN. Heart rate variability-a therapeutic target? J Clin Pharm Ther 2002;27:85-92.
11. Schmidt H, Müller-Werdan U, Nuding S, et al. Impaired chemoreflex sensitivity in adult patientswithmultiple organ dysfunction syndrome-the potential role of disease severity. Intensive Care Med 2004;30: 665-72.
12. Board of the European Society of Cardiology and North American Society of Pacing and Electrophysiology. Heart rate variability -standards of measurement, physiological interpretation, and clinical use. Eur Heart J 1996;17:354-81.
13. Taylor JA, Deborah LC, Myers CW, Eckberg DL. Mechanisms underlying very-low-frequency RR-interval oscillations in humans. Circulation 1998;98:547-55.
14. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
15. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996;22:707-10.
16. Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The task force on ACE-inhibitors of the European society of cardiology. Eur Heart J 2004;25:1454-70.
17. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006;367:413-8.
18. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001;33:1352-7.
19. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004;110:880-5.
20. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2006;32:75-9.
21. Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006;24:983-91.
22. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006;98:121-8.
23. Schieffer B, Bünte C, Witte J, et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 2004;44:362-8.
24. Hornig B, Landmesser U, Kohler Ch, et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease role of superoxide dismutase. Circulation 2001;103:799-805.
25. Landmesser U, Spiekermann S, Dikalov S, et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure. role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002;106:3073-8.
26. Gullestad L, Aukrust P, Ueland T, et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 1999;34:2061-7 [Comment in: J Am Coll Cardiol 1999;34:2068-71].
27. Hennen R, Friedrich I, Hoyer D, Nuding S, Rauchhaus M, Schulze M, Schlisske S, Schwesig R, Schlitt A, Buerke M, Müller-Werdan U, Werdan K, Schmidt H. Dtsch Med Wochenschr 2008;133:2500-5.
28. Hoyer D, Friedrich H, Zwiener U, et al. Prognostic impact of autonomic information in multiple organ dysfunction syndrome patients. Int J Cardiol 2006;108:359-69.
29. Hoyer D, Friedrich H, Frank B, et al. Autonomic information flow improves prognostic impact of task force HRV monitoring. Comput Methods Programs Biomed 2006;81:246-55.
30. Schmidt H, Hoyer D, Hennen R, Heinroth K, Rauchhaus M, Prondzinsky R, Hottenrott K, Buerke M, Müller-Werdan U, Werdan K. Autonomic Dysfunction Predicts Both One- and Two-Month Mortality in Middle-Aged Patients with Multiple Organ Dysfunction Syndrome. Crit Care Med 2008;36:967-70.
31. Averill DB, Diz DI. Angiotensin peptides and baroreflex control of sympathetic outflow: pathways and mechanisms of the medulla oblongata. Brain Res Bull 2000;51:119-28.
32. DiBona GF. Central sympathoexcitatory actions of angiotensin II: role of type 1 angiotensin II receptors. J Am Soc Nephrol 1999;10(11 Suppl):S90-4.
33. Lumbers ER, McCloskey DI, Potter EK. Inhibition by angiotensin II of baroreceptor-evoked activity in cardiac vagal efferent nerves in the dog. J Physiol 1979;24:6-80.
34. Potter EK. Angiotensin inhibits action of vagus nerve at the heart. B J Pharmacol 1982;75:9-11.
35. Townend JN, al-Ani M,West JN, LittlerWA, Coote JH. Modulation of cardiac autonomic control in humans by angiotensin II. Hypertension 1995;25:1270-5.
36. Osterziel KJ, Dietz R, Schmid W, Mikulaschek K, Manthey J, Kubler W. ACE inhibition improves vagal reactivity in patients with heart failure. Am Heart J 1990;120:1120-9.
37. Yee KM, Struthers AD. Endogenous angiotensin II and baroreceptor dysfunction: a comparative study of losartan and enalapril in man. Br J Clin Pharmacol 1998;46:583-8.
38. Flapan AD, Nolan J, Neilson JM, Ewing DJ. Effect of captopril on cardiac parasympathetic activity in chronic cardiac failure secondary to coronary artery disease. Am J Cardiol 1992;69:532-5.
39. Binkley PF, Haas GJ, Starling RC, et al. Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. J Am Coll Cardiol 1993;21: 655-61.
40. Bonaduce D, Marciano F, Petretta M, et al. Effects of converting enzyme inhibition on heart period variability in patients with acute myocardial infarction. Circulation 1994;90:108-13.
41. Kontopoulos AG, Athyros VG, Didangelos TP, et al. Effect of chronic quinapril administration on heart rate. Diabetes Care 1997;20:355-61.
42. Coats AJ. Ethical authorship and publishing. Int J Cardiol 2009;131: 149-50.